Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Hits New 1-Year Low – Should You Sell?

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $20.94 and last traded at $21.1050, with a volume of 719422 shares. The stock had previously closed at $21.95.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on FMS. Wall Street Zen upgraded shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 20th. UBS Group lowered Fresenius Medical Care AG & Co. KGaA from a “sell” rating to an “underperform” rating in a report on Wednesday, October 15th. Zacks Research downgraded Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 4th. The Goldman Sachs Group cut Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “neutral” rating in a research report on Tuesday. Finally, Truist Financial set a $28.00 price objective on Fresenius Medical Care AG & Co. KGaA in a report on Monday, January 5th. Four equities research analysts have rated the stock with a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Reduce” and an average target price of $28.00.

Fresenius Medical Care AG & Co. KGaA Price Performance

The firm has a fifty day moving average price of $23.33 and a two-hundred day moving average price of $24.96. The stock has a market capitalization of $12.39 billion, a P/E ratio of 15.41, a PEG ratio of 0.70 and a beta of 0.90. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.00 and a current ratio of 1.36.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last issued its quarterly earnings data on Tuesday, November 4th. The company reported $0.64 EPS for the quarter, topping the consensus estimate of $0.59 by $0.05. The company had revenue of $5.73 billion during the quarter, compared to analyst estimates of $4.72 billion. Fresenius Medical Care AG & Co. KGaA had a return on equity of 7.42% and a net margin of 3.72%. As a group, analysts expect that Fresenius Medical Care AG & Co. KGaA will post 1.51 EPS for the current fiscal year.

Institutional Investors Weigh In On Fresenius Medical Care AG & Co. KGaA

Several hedge funds and other institutional investors have recently made changes to their positions in FMS. TD Waterhouse Canada Inc. purchased a new position in shares of Fresenius Medical Care AG & Co. KGaA in the second quarter worth approximately $36,000. CIBC Private Wealth Group LLC increased its holdings in Fresenius Medical Care AG & Co. KGaA by 398.2% during the third quarter. CIBC Private Wealth Group LLC now owns 1,380 shares of the company’s stock valued at $36,000 after buying an additional 1,103 shares during the last quarter. Atlantic Union Bankshares Corp bought a new position in Fresenius Medical Care AG & Co. KGaA in the second quarter worth approximately $43,000. Hantz Financial Services Inc. raised its position in Fresenius Medical Care AG & Co. KGaA by 568.5% in the second quarter. Hantz Financial Services Inc. now owns 2,079 shares of the company’s stock worth $59,000 after acquiring an additional 1,768 shares during the period. Finally, Huntington National Bank boosted its stake in shares of Fresenius Medical Care AG & Co. KGaA by 219.5% during the 2nd quarter. Huntington National Bank now owns 2,355 shares of the company’s stock worth $67,000 after acquiring an additional 1,618 shares during the last quarter. Hedge funds and other institutional investors own 8.37% of the company’s stock.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high?flux dialyzers and bloodlines.